Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
25319 | 236 | 15.6 | 37% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
3619 | 884 | DOTARIZINE//DRUG INDUCED PARKINSONISM//CINNARIZINE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | THIETHANE | Author keyword | 3 | 100% | 1% | 3 |
2 | IMIDAZO2 1 FTHEOPHYLLINES | Author keyword | 2 | 67% | 1% | 2 |
3 | TRICYCLIC THEOPHYLLINE DERIVATIVES | Author keyword | 2 | 67% | 1% | 2 |
4 | ADENOSINE RECEPTORS ANTAGONISTS | Author keyword | 1 | 50% | 0% | 1 |
5 | BENZIMIDAZOQUINAZOLINE | Author keyword | 1 | 50% | 0% | 1 |
6 | DIMEPHOSPHONE NICOTINOYLHYDRAZONE | Author keyword | 1 | 50% | 0% | 1 |
7 | DIMEPHOSPHONE PYRIDINOYLHYDRAZONES | Author keyword | 1 | 50% | 0% | 1 |
8 | FUSED PURINES | Author keyword | 1 | 50% | 0% | 1 |
9 | NICOTINOYL HYDRAZONE | Author keyword | 1 | 50% | 0% | 1 |
10 | PYRIMIDINE 2 41H 3H DIONE | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 1 2 4TRIAZINO3 2 FPURINES | 3 | 100% | 1% | 3 |
2 | F FUSED THEOPHYLLINES | 3 | 100% | 1% | 3 |
3 | VITRO ANTIPROLIFERATIVE ACTIVITY | 2 | 44% | 2% | 4 |
4 | THEOPHYLLINES | 2 | 67% | 1% | 2 |
5 | CARDIAC IONIC CURRENTS | 1 | 38% | 1% | 3 |
6 | HETEROCYCLO PURINEDIONES | 1 | 100% | 1% | 2 |
7 | THIACYCLOBUTENE THIETE | 1 | 100% | 1% | 2 |
8 | TRICYCLIC THEOPHYLLINE DERIVATIVES | 1 | 50% | 1% | 2 |
9 | 3 SUBSTITUTED THIETANE 1 OXIDE | 1 | 50% | 0% | 1 |
10 | EPICHLOROHYDRINE | 1 | 50% | 0% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Annulated heterocyclo-purines II: Fused six- and more-membered heterocyclo-purinediones, -purinones and -purineimines | 2005 | 5 | 95 | 39% |
Annulated heterocyclo-purines I. Fused five-membered heterocyclo-purinediones, -purinones, and -purineimines | 2004 | 5 | 89 | 33% |
CONDENSED PURINES | 1992 | 2 | 66 | 38% |
SYNTHESIS OF N-SUBSTITUTED XANTHINES | 1991 | 4 | 22 | 27% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MED PHARMACOL MIZUHO KU | 1 | 25% | 0.8% | 2 |
2 | BEIJING BNLMS | 0 | 25% | 0.4% | 1 |
3 | PERM STATE PHARMACEUT | 0 | 14% | 0.4% | 1 |
4 | MED PHARMACEUT SHINJUKU KU | 0 | 13% | 0.4% | 1 |
5 | EA 4138 | 0 | 11% | 0.4% | 1 |
6 | S SETAGAYA KU | 0 | 10% | 0.4% | 1 |
7 | DEV S 132 MINAMIDAI | 0 | 100% | 0.4% | 1 |
8 | EP 105 CNRS | 0 | 100% | 0.4% | 1 |
9 | LA CNRS 09 | 0 | 100% | 0.4% | 1 |
10 | SCI MIZUHO KU | 0 | 100% | 0.4% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000121515 | META LEVEL INFERENCE//P TOLUENE SULFONYL CHLORIDE//CEREBRAL VASODILATOR |
2 | 0.0000119184 | ACCEPTOR BRIDGE DONOR//DIMER MODEL MOLECULE//EXOGENOUS ATP |
3 | 0.0000110618 | PYRAZOLO5 1 C1 2 4TRIAZOLES//HYDROLYSIS DECARBOXYLATION//PYRAZOLO TRIAZOLE |
4 | 0.0000103049 | HETEROCYCLIC SCAFFOLD//THE INTERNAL HEAVY ATOM EFFECT//ARYLNITRILE |
5 | 0.0000100556 | AGELASINE//PL BIOL SAKYO KU//ASMARINE |
6 | 0.0000093543 | 1 3 BENZOXAZIN 4 ONE//1 2 DIARYL 1 ETHANONE//MED EVALUAT CHEM |
7 | 0.0000091852 | PYRIDO2 3 DPYRIMIDINE//PYRANO4 3 DPYRIMIDINIUM SALTS//PYRIDO4 3 DPYRIMIDINIUM SALTS |
8 | 0.0000084599 | DIETHER LINKED//PROPRANOLOL ANALOG//BETA ADRENERGIC AGENT |
9 | 0.0000084572 | CENT FOOD FEED//1 2 4 TRIAZINE//PYRAZOLO5 1 C1 2 4TRIAZIN 4 ONES |
10 | 0.0000077242 | ACETYLENIC AMINO ACID//MULTISUBSTRATE INHIBITOR//COENZYME MODEL |